AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #

Size: px
Start display at page:

Download "AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #"

Transcription

1 Signal to cutoff (s/co) Copies per ml (c/ml) OVERVIEW AccuVert is a 5-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent serial bleeds collected from a single individual over a period of 14 days in 1998 during the development of an HIV infection and subsequent response. Each sample represents a single collection event. No preservatives were added. For Research Use Only. Not for use in diagnostic procedures. Data are provided for informational purposes. SeraCare Life Sciences does not claim that others can duplicate test results exactly. CAUTION: Potentially infectious materials. Follow Universal Precautions. The units that make up this panel were tested and found negative for anti-hcv and HBsAg. This does not ensure the absence of these or other human pathogens. Evolution of HIV Markers in Early Infection p24 Antigen HIV Antigen/Antibody /2 Antibody Antibody Positive cut-off (s/co) RNA 1.0E E E E E E E+00 This graph demonstrates the evolution of early HIV infection amongst panel members from the Organon Teknika ( RNA), Perkin Elmer ( p24 antigen), Dade Behring (HIV Antigen/Antibody), AxSym (/2 Antibody), and Genetic Systems ( Antibody) test methods. Page 1 of 6

2 Information SeraCare Batch # SeraCare Donor ID # Bleed Date Days Since 1 st Bleed NA 06-Jul NA 09-Jul NA 13-Jul NA 18-Jul NA 20-Jul RNA (copies/ml) 1 Chiron Quantiplex RNA 3.0 bdna Organon Teknika NASBA Roche Real Time PCR x x x x x x >5.0 x x x >5.0 x x 10 5 >8.0 x >5.0 x x x 10 5 Test Date 06-Jul Jul Jun-99 Test Site SC SC SC Kit Part Code Kit Lot No. Z007A Kit Exp. Date 15-Aug Feb Oct-99 Kit Regulatory Status NA NA NA 1 Positive/reactive results are noted in bold red. Page 2 of 6

3 HIV Antigen (s/co) 1 HIV Monoclonal EIA Coulter p24 Antigen Innogenetics p24 Innotest Perkin Elmer Alliance p24 Ag ELISA Test Date 24-Jun Jun Jul Dec-17 Test Site SC SC SC SC Kit Part Code 2A K-1048 NEK050A Kit Lot No M L Kit Exp. Date 02-Oct Aug Jan Aug-18 Kit Regulatory Status NA NA NA RUO ; RUO = Research Use Only HIV Antigen/Antibody (s/co) 1 BioMerieux VIDAS DUO Dade Behring Integral Organon Teknika Uni-Form II Roche Enzymun-Test > Test Date 23-Jul Jul Jul JuL-99 Test Site RL RL RL RL Kit Part Code OQTO Kit Lot No Kit Exp. Date 03-Sep Sep Jan Jan-01 RL = Reference Lab Page 3 of 6

4 /2 Antibody (s/co) 1 /2 EIA /2 AxSym 3 rd Generation /2 rdna EIA PLUS PRISM / > > Test Date 25-Jun Jul Jul Jul-99 Test Site SC RL RL RL Kit Part Code 3A77 9A44 7A84 4A27 Kit Lot No M LU HP HP00 Kit Exp. Date 25-Aug Oct Sep Oct-99 ; RL = Reference Lab /2 Antibody (s/co) 1 Sanofi Diagnostics Pasteur Access /2 Sanofi Diagnostics Pasteur Genscreen /2 Genetic Systems Murex /2 HIV 1.2.O > > >10.5 Test Date 23-Jul Jul Jun Jun-99 Test Site RL RL SC SC Kit Part Code GE94 Kit Lot No D011U 027RP1-05 F Kit Exp. Date 01-Oct Mar Nov Sep-99 ; RL = Reference Lab Page 4 of 6

5 /2 Antibody (s/co) 1 Ortho /2 Capture Ortho Vitros Eci /2 Roche DAGS Sanofi Fujirebio /2 PA Test Date 23-Jul Jul Aug Jul-99 Test Site RL RL RL RL Kit Part Code Kit Lot No. HVK B1033 MZ81204 Kit Exp. Date 31-Jul Aug Apr Dec-99 RL = Reference Lab Antibody (s/co) 1 EIA Organon Teknika Vironostika EIA Genetic Systems Test Date 09-Jul Jul Jul-99 Test Site SC SC SC Kit Part Code 3A Kit Lot No M QAA Kit Exp. Date 30-Jul Sep Apr-00 Kit Regulatory Status NA NA NA Page 5 of 6

6 Anti- Confirmatory 1 Cambridge Biotech Western Blot Band Pattern Cambridge Biotech Western Blot Result 01 f24 IND 02 f24 IND 03 f24 IND 04 f24 IND IND Test Date 02-Jul-99 Test Site SC Kit Part Code Kit Lot No. A Kit Exp. Date 29-Oct-99 Kit Regulatory Status 1 Western Blots are interpreted using ASTPHLD/CDC criteria (MMWR, vol. 38, S-7, 1989). Faintly staining bands are recorded, but interpreted as Indeterminate according to specific manufacturer's instructions. f = Faint; IND = Indeterminate NA The package insert for this panel can be found at. A printed copy of the package insert or data sheet may be requested by at info@seracare.com, or by phone at Page 6 of 6

HIV-1 AccuVert TM Seroconversion Panel

HIV-1 AccuVert TM Seroconversion Panel PACKAGE INSERT PRB954 (0600-0238) INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot test methods. Characterized

More information

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single

More information

HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #

HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch # s/co c/ml DATA SHEET OVERVIEW 0600-0248 (PRB966) is a 10-member panel of undiluted, naturally occurring plasma samples. Panel members represent serial bleeds collected from a single patient over the course

More information

AccuVert HIV-1 Seroconversion Panel PRB974 ( )

AccuVert HIV-1 Seroconversion Panel PRB974 ( ) PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers

More information

HIV-1 Seroconversion Panel PRB975

HIV-1 Seroconversion Panel PRB975 Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original

More information

AccuSet HCV Performance Panel

AccuSet HCV Performance Panel Signal to cutoff (s/co) DATA SHEET OVERVIEW AccuSet HCV (0810-0204) is a 25-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members

More information

AccuSet HIV-1/2 Performance Panel

AccuSet HIV-1/2 Performance Panel OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple

More information

HIV-1 Seroconversion Panel PRB964

HIV-1 Seroconversion Panel PRB964 A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers and clinical

More information

HIV-1 Seroconversion Panel

HIV-1 Seroconversion Panel OVERVIEW This Data Sheet contains test results specific for HIV-1. s are undiluted aliquots from plasma units collected from a single donor. No preservatives were added. CAUTION: Potentially infectious

More information

HIV-1 Seroconversion Panel PRB973

HIV-1 Seroconversion Panel PRB973 A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians

More information

HIV-1 Seroconversion Panel

HIV-1 Seroconversion Panel A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test

More information

AccuSet HBV Worldwide Performance Panel

AccuSet HBV Worldwide Performance Panel PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

Parvovirus B19 Mixed Titer Performance Panel PVP201

Parvovirus B19 Mixed Titer Performance Panel PVP201 A SERACARE PANEL PRODUCT INTENDED USE The is a panel of naturally occurring plasma specimens. This panel is intended for use by diagnostic manufacturers and clinical laboratories to evaluate their Parvovirus

More information

AccuSet Autoimmune Performance Panel

AccuSet Autoimmune Performance Panel PACKAGE INSERT 0840-0001 INTENDED USE The 0840-0001 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot autoimmune related test

More information

CARIBBEAN REGION EXTERNAL QUALITY ASSESSMENT SCHEME. Evaluation Booklet. Performance Evaluation Panel OPS0106 C. Coordination:

CARIBBEAN REGION EXTERNAL QUALITY ASSESSMENT SCHEME. Evaluation Booklet. Performance Evaluation Panel OPS0106 C. Coordination: EXTERNAL QUALITY ASSESSMENT SCHEME Evaluation Booklet CARIBBEAN REGION Performance Evaluation Panel OPS0106 C Coordination: Fundação Pró-Sangue Hemocentro de São Paulo Pan American Health Organization

More information

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Revised

More information

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like

More information

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

More information

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Mom Chandara, Msc, NIPH Team

Mom Chandara, Msc, NIPH Team Mom Chandara, Msc, NIPH Team EXTERNAL QUALITY ASSESSMENTS (EQAS) EQA refers to a system in which laboratory results are scrutinized objectively by an outside agency in order to get a general impression

More information

FINAL REPORT HBV Serology External Quality Assessment Scheme

FINAL REPORT HBV Serology External Quality Assessment Scheme FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Mar/11 HBV Serology EQAS Panel ID 2008/Mar/11 Page 1 of 9 The NRL is a: NATA-accredited proficiency

More information

Confirmatory Testing Algorithm. Routine Donor Testing Algorithm

Confirmatory Testing Algorithm. Routine Donor Testing Algorithm Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution

More information

Curators of the University of Missouri - Combined January 1, 2016 through December 31, 2016

Curators of the University of Missouri - Combined January 1, 2016 through December 31, 2016 Cost Management Report Delta Dental Network Coverage Network Utilization Discount Delta Dental PPO Network 28.3% 29.4% Delta Dental Premier Network 67.0% 12.0% Total 95.3% Savings Categories $ % of Net

More information

HIV testing has significantly improved

HIV testing has significantly improved HIV testing: an update By Nicola Zetola, MD, and Jeffrey D. Klausner, MD, MPH HIV testing has significantly improved since the first diagnostic test in 1985. Increased understanding of HIV transmission

More information

Routine HIV Testing Community of Practice Session #2

Routine HIV Testing Community of Practice Session #2 Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing

More information

FINAL REPORT HBV Serology External Quality Assessment Scheme

FINAL REPORT HBV Serology External Quality Assessment Scheme FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Oct/28 HBV Serology EQAS Panel ID 2008/Oct/28 Page 1 of 11 The NRL is a: NATA-accredited proficiency

More information

Situation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011

Situation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients

More information

SUPPLIER/MANUFACTURER PERFORMANCE REPORT

SUPPLIER/MANUFACTURER PERFORMANCE REPORT 80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR, PATHUMTHANI 30, THAILAND TEL : (66-) 9958 9, 995330 FAX : (66-) SUPPLIER/MANUFACTURER PERFORMANCE REPORT 80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR,

More information

100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010

100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010 Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories

More information

NATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal

NATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal NATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal Valerie Bevan Department for Evaluations and Standards Laboratory Centre for Infections Health Protection Agency October 2008 Structure of talk

More information

Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma

Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma Test Name *Minimum Collection Tubes Sample Stability ABO/Rh Blood Typing 50 µl cells EDTA whole blood (lavender-top) Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma

More information

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.

More information

McLean ebasis plus TM

McLean ebasis plus TM McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797

More information

FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?

FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members

More information

Curators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report

Curators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report Cost Management Report Program Design Specifics Standard Claims Management SAVINGS CATEGORIES SAVINGS RESULTS % OF NET SUBMITTED DOLLARS % OF PAID DOLLARS Deductible Applied $1,296,627 5.68% 9.78% Patient

More information

Tri-County Opioid Safety Coalition Data Brief December 2017 Clackamas, Multnomah, and Washington Counties

Tri-County Opioid Safety Coalition Data Brief December 2017 Clackamas, Multnomah, and Washington Counties Medicaid-Funded Alternative Treatment for Back Pain in the Tri-County Region Key Findings The percentage of members with a back pain diagnosis who received an alternative treatment increased from 29% in

More information

Human Immunodeficiency Virus Serology

Human Immunodeficiency Virus Serology Participant No: _ Human Immunodeficiency Virus Serology Survey No: RT :20 Please print the document labelled Clinical Notes & Test Instructions and enter your results via myqap. Kit Information Please

More information

HIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center

HIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated

More information

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa

More information

Sleep Market Panel. Results for June 2015

Sleep Market Panel. Results for June 2015 Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital

More information

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26 1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary

More information

Diagnostic Tests for HIV

Diagnostic Tests for HIV Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,

More information

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

More information

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance 18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted

More information

HumaTex CRP. Design Verification. Contents

HumaTex CRP. Design Verification. Contents Design Verification HumaTex CRP Contents 1 Function... 2 2 Reproducibility... 2 3 Sensitivity and dynamic range... 2 Preparation of serum control panel... 2 Sensitivity test results... 2 Prozone check...

More information

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental

More information

T pallidum. Table of contents

T pallidum. Table of contents An assessment of Point of Care Tests for Hepatitis B, Hepatitis C, HIV and Syphilis for use in an Operational Environment to Provide Emergency Transfusion Support Microbiological Diagnostics Assessment

More information

Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station

Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station Click here for the corrections made < Reference > December 3, 212 Tokyo Electric Power Company Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station * As of

More information

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision

More information

Blood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.

Blood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

STARHS/RITA and Misclassification

STARHS/RITA and Misclassification Optimization and Calibration of Less Sensitive and Avidity Modified Protocols for the Vitros Immunodiagnostic Products Anti-HIV- 1+2 Assay for Detection of Early HIV Infections Sheila M. Keating, Debra

More information

Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting

Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Eric B. Durbin, DrPH, MS, Director of Cancer Informatics Frances E. Ross, CTR,

More information

FGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS

FGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021

More information

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC) HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC

More information

Quit Rates of New York State Smokers

Quit Rates of New York State Smokers Quit Rates of New York State Smokers Sara M. Abrams, MPH Data Manager NYS Smokers Quitline Sara.Abrams@roswellpark.org September 6, 20 Presentation Outline Basic Quitline Service How Quit Rates are defined

More information

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE TITLE : SOP for (off board dilution) Less Sensitive Modified VITROS Enzyme Immunoassay CEPHIA DOCUMENT

More information

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD SOURCES OF VARIATION (RANDOM VS SYSTEMATIC) MAGNITUDE OF EACH SOURCE CONSEQUENCES FOR CONFIDENCE LIMITS AROUND MEASUREMENTS AND CHANGES DATA FROM ROCHE HIV

More information

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27 1 The National Laboratory for HIV Reference Services is Accredited to ISO 15189 and ISO 17043 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology

More information

Product Information and Testing - Amended. Product Information

Product Information and Testing - Amended. Product Information Product Information and Testing - Amended Product Information Product Name ips(foreskin)-3 Alias ips(foreskin) clone (#3) Lot Number WB0002 Depositor University of Wisconsin Laboratory of Dr. James Thomson

More information

HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings

HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Elizabeth M. Dax with the staff of the National Serology Reference Laboratory, Australia My Background Worked in HIV

More information

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19

More information

VIDRL & WHO Measles IgM Proficiency Panel Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL

VIDRL & WHO Measles IgM Proficiency Panel Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL VIDRL & WHO Measles IgM Proficiency Panel 00702 Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL Table of Contents Tables and Figures... 3 Abbreviations... 4 Introduction...

More information

An Updated Approach to Colon Cancer Screening and Prevention

An Updated Approach to Colon Cancer Screening and Prevention An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention

More information

Disclosures. Learning Objectives. Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement

Disclosures. Learning Objectives. Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement Alix Casler, M.D., F.A.A.P. Medical Director of Pediatrics, Orlando Health Physician Associates

More information

2018 HIV and HCV Diagnostic Testing Survey

2018 HIV and HCV Diagnostic Testing Survey 2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will

More information

Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)

Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc) Date: 6 January 2012 Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc) WHO Collaborating Centre for HIV/AIDS Diagnostic and Laboratory Support Department of Clinical Sciences

More information

The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing

The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides

More information

Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers

Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special

More information

HIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED

HIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department

More information

Simple Solutions for Patient Monitoring. Maximum Flexibility 2 Configuration: 8 to 1000 viral load tests/day 2 Sample: Plasma/DBS

Simple Solutions for Patient Monitoring. Maximum Flexibility 2 Configuration: 8 to 1000 viral load tests/day 2 Sample: Plasma/DBS Simple Solutions for Patient Monitoring What is the interest of having a high level of sensitivity? Higher sensitivity means you are able to offer better patient monitoring, particularly in the low viral

More information

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town HOPE Follow-Up Algorithm: Unusual Cases Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town MTN-025 Testing Algorithm Screening/Enrollment MTN-025 Testing Algorithm

More information

TB Outbreak in a Homeless Shelter

TB Outbreak in a Homeless Shelter TB Outbreak in a Homeless Shelter Objectives Epidemiology of Outbreak Population Health Interventions Population Health Goals 2007 One active case identified Less than compliant Prolonged recovery Contact

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

Date : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark

Date : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A

More information

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Aim: Project focus to embed evidence based protocol for the treatment of Constipation in the

More information

Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019

Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 20-Jan 21-Jan 22-Jan 23-Jan 24-Jan 25-Jan 26-Jan between January 14th - January 21st Please Note: The application deadline

More information

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex anti-hcv (version 4.0) Number: PQDx

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex anti-hcv (version 4.0) Number: PQDx WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex anti-hcv (version 4.0) Number: PQDx 0164-059-00 Abstract Murex anti-hcv (version 4.0) with product codes 7F51-01 and

More information

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx

WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex HIV Ag/Ab Combination Number: PQDx 0144-043-00 Abstract Murex HIV Ag/Ab Combination with product codes 7G79-09 (GE41,

More information

Armed Services Blood Program

Armed Services Blood Program Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009

More information

HTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22

HTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLS425 2015Oct22

More information

South Plains Emergency Medical Services, Inc. P.O. Box Lubbock, Texas 79453

South Plains Emergency Medical Services, Inc. P.O. Box Lubbock, Texas 79453 South Plains Emergency Medical Services, Inc. P.O. Box 53597 Lubbock, Texas 79453 June 28, 2017 TO: SPEMS EMS Services SUBJECT: SPEMS PARAMEDIC PROTOCOL VARIANCE With the ongoing medication shortages,

More information

ESPnet: An Overview of Electronic Case Reporting using EHRs

ESPnet: An Overview of Electronic Case Reporting using EHRs ESPnet: An Overview of Electronic Case Reporting using EHRs Kevin Cranston, MDiv Assistant Commissioner Director, Bureau of Infectious Disease and Laboratory Sciences Massachusetts Department of Public

More information

Improving care of HIV-infected breastfeeding

Improving care of HIV-infected breastfeeding Improving care of HIV-infected breastfeeding and their : Early results from the Partnership for HIV-free Survival Initiative in Uganda Tamara Nsubuga-Nyombi, URC IAS- Melbourne, Australia July 22nd, 2014

More information

BREATH AND BLOOD ALCOHOL STATISTICS

BREATH AND BLOOD ALCOHOL STATISTICS BREATH AND BLOOD ALCOHOL STATISTICS 116 MOTOR VEHICLE CRASHES IN NEW ZEALAND 213 BREATH AND BLOOD ALCOHOL STATISTICS 117 CONTENTS TABLES Table 1 Number of alcohol offenders by age group and sex 119 Table

More information

Dementia Content Report May Produced By The NHS Choices Reporting Team

Dementia Content Report May Produced By The NHS Choices Reporting Team Dementia Content Report May 2013 Produced By The NHS Choices Reporting Team CH.NHSChoices-Reporting@nhs.net 35.0M 30.0M 25.0M 20.0M 15.0M 10.0M 5.0M 0.0 15.9M Overall Choices Site Visits NHS Choices Policy

More information

From Analytics to Action

From Analytics to Action From Analytics to Action Overview So, what are we talking about here? How to make incremental changes to your digital content that will result in positive user actions Overview Rooted in the hard sciences

More information

Monitoring, Evaluation, and Reporting (MER) Guidance (v2.3): PMTCT. Presenter: Jenny Albertini, S/GAC Date: October 2018

Monitoring, Evaluation, and Reporting (MER) Guidance (v2.3): PMTCT. Presenter: Jenny Albertini, S/GAC Date: October 2018 Monitoring, Evaluation, and Reporting (MER) Guidance (v2.3): PMTCT Presenter: Jenny Albertini, S/GAC Date: October 2018 Video Outline Section 1: Overview of the technical area and related indicators Section

More information

EQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information

EQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information (BC80) : December 2014 December 20 Exceptions None at this time. Legend: No Warnings Missing Result Late Results < < > * Amended Result (per participant s request) News Customer Information Please refer

More information

Documentation, Codebook, and Frequencies

Documentation, Codebook, and Frequencies 2 Documentation, Codebook, and Frequencies Laboratory Component: Hepatitis B: core antibody, surface antibody and surface antigen; Hepatitis C: confirmed antibody; Hepatitis D antibody Survey Years: 2003

More information

Marketing on a Budget: Monthly quit & win challenges to drive quitline utilization. Presenters: John Atkinson & Elizabeth Harvey

Marketing on a Budget: Monthly quit & win challenges to drive quitline utilization. Presenters: John Atkinson & Elizabeth Harvey Marketing on a Budget: Monthly quit & win challenges to drive quitline utilization Presenters: John Atkinson & Elizabeth Harvey WHAT IS THE FIRST WEEK CHALLENGE? Monthly campaign Register online or by

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging 16 January 2017 Attachment 3 URGENT FIELD SAFETY NOTICE FSCA3193 Etest Ceftriaxone TXL32 (Ref. 412302, 412303) SPB Packaging Dear This letter is intended for all ETEST Ceftriaxone TXL32 (Ref. 412302, 412303)

More information